{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:30:07Z","timestamp":1791009007311,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.leukres.2024.107541","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T15:10:44Z","timestamp":1718291444000},"page":"107541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Unmutated IGHV at diagnosis in patients with early stage CLL independently predicts for shorter follow-up time to first treatment (TTFT)"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0793-264X","authenticated-orcid":false,"given":"Piero","family":"Galieni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Troiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Picardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Angelini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mestichelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Dalsass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Maravalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Camaioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catia","family":"Bigazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Caraffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriana","family":"Ruggieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Mazzotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Mattioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Angelini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.leukres.2024.107541_bib1","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2024.107541_bib2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2024.107541_bib3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.leukres.2024.107541_bib4","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"International CLL-IPI working\u00a0group","year":"2016","journal-title":"Lancet Oncol."},{"issue":"25","key":"10.1016\/j.leukres.2024.107541_bib5","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2024.107541_bib6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib\u2013rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2024.107541_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.leukres.2024.107541_bib8","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2024.107541_bib9","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/bjh.17984","article-title":"Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials","volume":"196","author":"Allan","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.leukres.2024.107541_bib10","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/ajh.24493","article-title":"The chronic lymphocytic leukemia international prognostic index (CLL-IPI) predicts time to first treatment in early CLL: independent validation in a prospective cohort of early stage patients","volume":"91","author":"Molica","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.leukres.2024.107541_bib11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1182\/blood.2020009813","article-title":"The CLL international prognostic index predicts outcomes in monoclonal B-cells lymphocytosis and Rai 0 CLL","volume":"138","author":"Parikh","year":"2021","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.leukres.2024.107541_bib12","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood.2019003453","article-title":"International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia","volume":"135","author":"Condoluci","year":"2020","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2024.107541_bib13","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/ajh.25831","article-title":"Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index","volume":"95","author":"Kleinstern","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2024.107541_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.684621","article-title":"Lymphocyte doubling time as a key prognostic factor to predict time to first treatment in early-stage chronic lymphocytic leukemia","volume":"11","author":"Morabito","year":"2021","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2024.107541_bib15","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson","year":"1996","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2024.107541_bib16","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1182\/blood-2006-02-005322","article-title":"Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80\u2009% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression","volume":"108","author":"Dicker","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2024.107541_bib17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/gcc.20433","article-title":"Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes","volume":"46","author":"Haferlach","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.leukres.2024.107541_bib18","series-title":"ISCN 2020: An International System for Human Cytogenomic Nomenclature","year":"2020"},{"key":"10.1016\/j.leukres.2024.107541_bib19","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2024.107541_bib20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/sj.leu.2403242","article-title":"Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis","volume":"18","author":"Cuneo","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107541_bib21","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2141.2008.07227.x","article-title":"Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis","volume":"142","author":"Cavazzini","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2024.107541_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2404457","article-title":"European Research Initiative on CLL. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia","volume":"21","author":"Ghia","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107541_bib23","doi-asserted-by":"crossref","first-page":"W503","DOI":"10.1093\/nar\/gkn316","article-title":"IMGT\/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis","volume":"36","author":"Brochet","year":"2008","journal-title":"Nucleic Acids Res."},{"issue":"23","key":"10.1016\/j.leukres.2024.107541_bib24","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1093\/bioinformatics\/btx423","article-title":"GLASS: assisted and standardized assessment of gene variations from Sanger sequence trace data","volume":"33","author":"Pal","year":"2017","journal-title":"Bioinformatics"},{"issue":"4","key":"10.1016\/j.leukres.2024.107541_bib25","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/leu.2014.297","article-title":"Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia","volume":"29","author":"Malcikova","year":"2015","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.leukres.2024.107541_bib26","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","article-title":"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia","volume":"127","author":"Nadeu","year":"2016","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.leukres.2024.107541_bib27","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood-2013-11-539726","article-title":"Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia","volume":"123","author":"Rossi","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2024.107541_bib28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.12539","article-title":"Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia","volume":"163","author":"Jethwa","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"446","key":"10.1016\/j.leukres.2024.107541_bib29","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J. Am. Stat. Assoc."},{"issue":"3","key":"10.1016\/j.leukres.2024.107541_bib30","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann. Stat."},{"issue":"6","key":"10.1016\/j.leukres.2024.107541_bib31","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2024.107541_bib32","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2024.107541_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2024.107541_bib34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrc.2016.8","article-title":"The molecular pathogenesis of chronic lymphocytic leukemia","volume":"16","author":"Fabbri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.leukres.2024.107541_bib35","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11899-014-0223-4","article-title":"Risk factors for Richter syndrome in chronic lymphocytic leukemia","volume":"9","author":"Parikh","year":"2014","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"12","key":"10.1016\/j.leukres.2024.107541_bib36","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/ajh.24808","article-title":"IGHV mutational status testing in chronic lymphocytic leukemia","volume":"92","author":"Crombie","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.leukres.2024.107541_bib37","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ajh.24660","article-title":"Chronic lymphocytic leukemia: a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI","volume":"92","author":"Delgado","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.leukres.2024.107541_bib38","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3390\/diagnostics11050853","article-title":"The evolving landscape of chronic lymphocytic leukemia on diagnosis, prognosis and treatment","volume":"11","author":"P\u00e9rez-Carretero","year":"2021","journal-title":"Diagnostics"},{"issue":"8","key":"10.1016\/j.leukres.2024.107541_bib39","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/s41375-020-0747-7","article-title":"Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial","volume":"34","author":"Herlin","year":"2020","journal-title":"Leukemia"},{"issue":"31","key":"10.1016\/j.leukres.2024.107541_bib40","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1200\/JCO.2010.33.9002","article-title":"Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia","volume":"29","author":"Wierda","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2024.107541_bib41","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1038\/s41375-021-01149-w","article-title":"Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients","volume":"35","author":"Baumann","year":"2021","journal-title":"Leukemia"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T19:46:02Z","timestamp":1722973562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624001073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":41,"alternative-id":["S0145212624001073"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107541","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unmutated IGHV at diagnosis in patients with early stage CLL independently predicts for shorter follow-up time to first treatment (TTFT)","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107541","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107541"}}